A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
NCT00585000
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
49
Enrollment
INDUSTRY
Sponsor class
Stopped
See termination reason in detailed description.
Conditions
Melanoma
Interventions
DRUG:
CP-675,206
Sponsor
AstraZeneca